Skip to content

Search

Species-Specific and Cross-Reactive IgG1 Antibody Binding to Viral Capsid Protein 1 (VP1) Antigens of Human Rhinovirus Species A, B and C

Human rhinoviruses (HRV) are associated with upper and lower respiratory illnesses, including severe infections causing hospitalization in both children...

Recombinant house dust mite allergens

House dust mites (HDM) are a globally important source of allergen responsible for the sensitization of more than 50% of allergic patients.

Protective anti-outer membrane protein immunity against Pasteurella pneumotropica infection of mice

The proteins examined were the homologues of the P4, P6, P26, and D15 proteins of Haemophilus influenzae.

Innate affairs of allergens

Activation of receptors of the innate immune system is a critical step in the initiation of immune responses.

Antibacterial antibody responses associated with the development of asthma in house dust mite-sensitised and non-sensitised children

We aimed to measure the antibody development to 2 bacteria in a birth cohort at high risk of allergic disease, and to assess which responses are asthma-linked.

A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei

Scabies infestations are difficult to diagnose clinically and current serologic tests have less than 50% accuracy...

CD4 allergen tetramers

The introduction of class II tetramers for identifying antigen-binding CD41 cells has lagged behind the use of class I tetramers because of difficulties...

Barriers and Considerations for Diagnosing Rare Diseases in Indigenous Populations

Advances in omics and specifically genomic technologies are increasingly transforming rare disease diagnosis. However, the benefits of these advances are disproportionately experienced within and between populations, with Indigenous populations frequently experiencing diagnostic and therapeutic inequities. The International Rare Disease Research Consortium (IRDiRC) multi-stakeholder partnership has been advancing toward the vision of all people living with a rare disease receiving an accurate diagnosis, care, and available therapy within 1 year of coming to medical attention. In order to further progress toward this vision, IRDiRC has created a taskforce to explore the access barriers to diagnosis of rare genetic diseases faced by Indigenous peoples, with a view of developing recommendations to overcome them.